mustard oil
Allyl isothiocyanate (AITC), also known as mustard oil, is one of the most common naturally occurring isothiocyanates, which occurs in many common cruciferous vegetables. Besides antimicrobial activity against a wide spectrum of pathogens, it showed anticancer activity in both cultured cancer cells and animal models, although the underlining mechanisms remain largely undefined. Allyl isothiocyanate is a TRPA1 and TRPV1 agonist and pungency and lachrymatory effects of Allyl isothiocyanate are mediated through the TRPA1 and TRPV1 ion channels. Allyl isothiocyanate irritates the mucous membranes and induces eczematous or vesicular skin reactions. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started May 23, 2022 (NCT05354453)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
SMILES
C=CCN=C=S- Mol. weight
- 99.154 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSBN34FX42G3 ↗
- ChEMBLCHEMBL233248 ↗
Also known as
- mustard oil
- mustard oil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06809569 | Phase 1 | Sep 25, 2023 | Merck |
| NCT05354453 | Phase 1 | May 23, 2022 | Boehringer Ingelheim |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2022 |
| Merck | For profit | 1 | 1 | 1 | 2023 |